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Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy with 
reduced ejection fraction that affects women late in pregnancy or the months following 
delivery [1]. It is a global disease with various geographical incidence and previously reported
mortality across selected European centers was 4% at 6-month follow-up and higher in other 
continents [2, 3]. In the Danish population, the incidence of PPCM was 1:10 149 and at 1 year
3.3% had died [4]. The aim of this study was to examine long-term all-cause mortality in a 
Swedish nationwide cohort of patients with a history of PPCM.
This retrospective observational study included all patients who received the 
diagnosis of PPCM, International Classification of Diseases, tenth revision, (ICD-10) code 
O90.3, in The Swedish National Patient Register for both inpatient and outpatient specialist 
care episodes between 1997 and 2014 [5]. This was merged with data from the Swedish Cause
of Death Register for the same time period. Data were described as frequencies, percentages, 
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and means including standard deviations (±). The Kaplan‐Meier estimator was used to 
describe survival. The cumulative incidence of death was calculated using time to death as the
censoring event; otherwise, total time of follow‐up was used for patients who were still alive. 
The software program SPSS version 25 (IBM, Armonk, NY) was used for analyses.
The sample consisted of 150 patients with the diagnosis of PPCM. The mean 
age at diagnosis was 34.6 ± 6.3 years and mean follow-up time 5.3 ± 4.29 years. Median year 
at the time of the diagnosis was 2010, with an interquartile range of 5 years. During the study 
period 5 (3.3%) patients died from any cause. Kaplan-Meier estimated cumulative incidence 
of death was at 1-year 2.1%, 3-years 3.2%, 5-years 3.2%, and at 10-years 5.5%. Figure 1 
shows a Kaplan-Meier plot of estimated cumulative survival. Out of the 5 deaths, the main 
cause of death was cardiovascular disease in 4 cases and infectious disease in 1 case.
The National Board of Health and Welfare of Sweden provides data regarding 
the number of deliveries for the year 1997 up until 2014 [6]. Using these data the incidence of
PPCM could be calculated for each year (Fig. 2). There was an increasing incidence of PPCM
per 100,000 deliveries during the study period, ranging from 1.2 in 1997 up to 22.5 in 2012, 
likely in part due to improved diagnostics and use of the ICD-10 code. In the Danish registry-
based study the incidence was 1 in every 10,149 deliveries during the period 2005–2014 [4], 
the incidence in Sweden for the same period was 1 in every 11,014 deliveries.
The long-term prognosis of PPCM in the Swedish setting is good. Nevertheless, 
PPCM is a potentially life-threatening condition that requires careful attention in each 
individual case.
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Figure 1. Kaplan-Meier estimate of cumulative survival for 150 patients with peripartum 
cardiomyopathy.
Figure 2. Incidence of peripartum cardiomyopathy (PPCM) diagnosis per 100,000 deliveries 
in Sweden for the years 1997–2014.


